At what enterprise value was SERB acquired in 2017?

During the acquisition of SERB by CHARTERHOUSE in 2017, the transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR.

What was the EV/EBITDA of SERB when it was acquired by CHARTERHOUSE?

The estimated EV/EBITDA multiple for SERB is in the range of 10x - 18x.

When was SERB acquired by CHARTERHOUSE?

SERB was acquired by CHARTERHOUSE in 2017.

What was the revenue of SERB at the time of the deal?

The revenue of SERB at the time of the deal is estimated to be in the range of 50M - 100M EUR.

What was the EBITDA of SERB during the acquisition?

SERB's EBITDA is estimated to be in the range of 10M - 30M EUR.

How is the data for the SERB acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the SERB deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.charterhouse.co.uk/news/charterhouse-capital-partners-invests-in-serb-to-accelerate-its-development/

← DATABASE

Home Database Healthcare & PharmaSERB

06/2017

SERB acquired by CHARTERHOUSE

BELGIUM Life Sciences / Pharma & Biotech EV 300M - 700M EUR

Context

This transaction involves Charterhouse successfully acquiring a controlling majority stake in SERB. The operation is meticulously structured to perfectly align with the target's existing executive leadership. The historical controlling shareholder and the incumbent management team are significantly reinvesting their proceeds to retain a robust equity position while continuing to lead day-to-day operations. Charterhouse utilizes its latest flagship investment vehicle to capitalize this partnership. The primary strategic rationale underpinning the deal is to massively accelerate SERB's developmental roadmap. The freshly injected capital and strategic guidance will be explicitly deployed to fuel ongoing geographic expansion and aggressively pursue the continuous acquisition of complementary specialty pharmaceutical products and synergistic businesses.

SERB, which reported an EBITDA margin of in 2016, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in Belgium, SERB is a prominent, independent European pharmaceutical company specializing strictly in niche branded prescription medicines. The firm focuses heavily on highly specific therapeutic areas, including critical and emergency care, neurology, diagnostics, and endocrinology. Operating through multiple established offices across Europe and expanding actively into North America, the company boasts an exceptionally stable and fast-growing product portfolio. Its historical success is deeply rooted in a dual strategic approach: driving robust organic growth while successfully executing targeted acquisitions of niche pharmaceutical products possessing significant growth potential.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2016

2015

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
10/2017	CVC	SEBIA	FRANCE	Diagnostic Equipment
09/2017	FRESENIUS	NXSTAGE MEDICAL	UNITED STATES	Diagnostic Equipment
06/2017	EQT PARTNERS	OTTOBOCK	GERMANY	Implants & Prosthetics
05/2017	PAI PARTNERS	ELITECH GROUP	FRANCE	Diagnostic Equipment
04/2017	BAIN CAPITAL / CINVEN	STADA	GERMANY	Generics / Labs
04/2017	NORDSON CORPORATION	VENTION ADVANCED TECHNOLOGIES	UNITED KINGDOM	Medical Devices
03/2017	ARDIAN	UNITHER	FRANCE	CDMO
02/2017	ECOLAB	LABORATOIRES ANIOS	FRANCE	Medical Consumables
09/2016	ARCHIMED	POLYPLUS	FRANCE	R&D Biotech
09/2016	ARDIAN / IXO PRIVATE EQUITY	LAGARRIGUE	FRANCE	Implants & Prosthetics

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 50M - 100M EUR

EBITDA range: 10M - 30M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SERB by CHARTERHOUSE are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: serb

Acquirer: charterhouse